Figure 1. Schematic representation of the mammalian cell cycle. The distinct phases of the mammalian cell cycle, including quiescence (G 0 ), Gap 1 (G 1 ), DNA synthesis (S), Gap2 (G 2 ), and mitosis (M) are indicated. Those Cdk/cyclin complexes thought to drive each of these phases are also indicated. Cdk? represents a putative Cdk responsible for mediating the inhibitory activity of the Cip/Kip proteins in G 1 and/or driving DNA synthesis in the absence of Cdk2. Boxes on the right side indicate whether each of these molecules is essential for cell cycle progression based on genetic studies using gene-targeted mice. For more details see Table 1 .
To ensure proper progression through the cell cycle, cells have developed a series of checkpoints that prevent them from entering into a new phase of the cycle until they have successfully completed the previous one. Recently divided or quiescent cells also must pass certain checkpoints before they enter a new cycle. For instance, these cells must determine whether they have all the necessary nutrients to carry out cell division. They also need to sense that they have reached proper homeostatic cell size, otherwise they will decrease (or increase) in size with each round of division. Metazoans must also control the number of cells in every organ, a parameter that, coupled with cell size, ultimately determines the size of every individual. In addition, cells must control the amount of mitogenic information required to enter the cycle (for review, see Malumbres and Barbacid 2001) . Too stringent requirements would prevent cell proliferation at critical times such as during wound healing or to fight an infection. On the other hand, overly relaxed controls would lead to unscheduled proliferation and possibly neoplastic growth.
The mammalian cell cycle (see Fig. 1 ) is thought to be driven by heterodimeric kinases composed of a catalytic subunit known as cyclin-dependent kinase (Cdk) and a regulatory subunit, designated as cyclin. Two of these Cdks, Cdk4 and Cdk6, bind to and are activated by the Dtype family of cyclins, D1, D2, and D3 (for review, see Sherr and Roberts 1999) . The D-type cyclins are critical integrators of mitogenic signaling since their synthesis is one of the main endpoints of the Ras/Raf/MAPK signaling pathway. Interestingly, mouse embryonic fibroblasts that lack the three D-type cyclins can proliferate, indicating that these molecules are not strictly necessary for progression through G 1 (Kozar et al. 2004; see below) . Whether this activity is mediated by other cyclins, or by alternative mechanisms, remains to be resolved.
The primary role of the D-type cyclin/Cdk4 or Cdk6 complexes is to phosphorylate members of the retinoblastoma (Rb) protein family, pRb, p107, and p130. The Rb proteins are tumor suppressors that in their active, nonphosphorylated state prevent expression of genes necessary for DNA replication (S phase of the cell cycle) and mitosis (M phase). Phosphorylation of pRb by D-type cyclin/Cdk4 or Cdk6 complexes results in its partial inactivation, which, in turn, allows expression of a limited number of transcriptional targets needed to drive cells through the G 1 phase of the cell cycle (for review, see Co- The distinct phases of the mammalian cell cycle, including quiescence (G 0 ), Gap 1 (G 1 ), DNA synthesis (S), Gap2 (G 2 ), and mitosis (M) are indicated. Those Cdk/cyclin complexes thought to drive each of these phases are also indicated. Cdk? represents a putative Cdk responsible for mediating the inhibitory activity of the Cip/Kip proteins in G 1 and/or driving DNA synthesis in the absence of Cdk2. Boxes on the right side indicate whether each of these molecules is essential for cell cycle progression based on genetic studies using gene-targeted mice. For more details see Table 1. brinik 2005). Some of these targets include the E-type cyclins (E1 and E2), whose primary role is to activate Cdk2. Active E-type cyclin/Cdk2 complexes further phosphorylate pRb, leading to a wave of transcriptional activity essential to proceed through the G 1 /S transition. Cdk activity can be negatively regulated by Cdk inhibitors (CKI). CKIs come in two flavors. The four- member INK4 family (p16  INK4a , p15  INK4b , p18  INK4c , and  p19 INK4d ) exerts its inhibitory activity by binding to the Cdk4 and Cdk6 kinases and preventing their association with D-type cyclins (Sherr and Roberts 1999) . Although INK4 proteins are biochemically indistinguishable from each other in vitro, they are expressed at different times during embryonic and postnatal development. Moreover, generation of gene-targeted mice deficient for each of these proteins has revealed significant functional differences (for review, see Ortega et al. 2002) . The three members of the Cip/Kip family, p21
Cip1 , p27 Kip1 , and p57 Kip2 , form heterotrimeric complexes with all the G 1 /S Cdks and their cognate cyclins (Sherr and Roberts 1999) . However, in stoichiometric amounts, they preferentially inhibit the kinase activity of Cdk2/cyclin E complexes (see below).
CELL CYCLE AND CANCER
Molecular analysis of human tumors has revealed frequent mutations and epigenetic changes within cell cycle regulators (Malumbres and Barbacid 2001) . Most of these molecular alterations occur in G 1 regulators, thus underscoring the importance of maintaining proper control of cell cycle commitment to prevent human cancer. They include overexpression of cyclins (mainly cyclins D1 and E1) and Cdks (mainly Cdk4 and Cdk6) as well as loss of CKI expression (mainly p16   INK4a   , p15 INK4b , and p27 Kip1 ) and of pRb. Moreover, Cdk4 has been found mutated in familial melanoma. Although most of these tumor-associated alterations result from DNA mutations, it is becoming increasingly evident that epigenetic silencing of certain promoters (e.g., p16
INK4a , p15 INK4b , or pRb) also plays a significant role in tumor development (for review, see Esteller 2005) .
Direct genetic or epigenetic alteration of Cdk2 has been rarely described. Yet, expression of some of its most direct regulators, p27
Kip1 and cyclin E1, is frequently altered in human tumors, changes that often correlate with poor prognosis (for review, see Yamasaki and Pagano 2004) . Within the Rb protein family, loss or inactivation of pRb is a rather frequent event in human tumors. However, p130 is less frequently lost, and p107 inactivation has not been reported (for review, see Paggi and Giordano 2001) . These observations suggest that p107 and p130 may play a primary role in promoting differentiation rather than proliferation, a concept supported by results obtained with gene-targeted mice (for review, see Classon and Harlow 2002) . Finally, mutations in the E2F family of transcription factors have not been observed in human tumors.
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Cold Spring Harbor Laboratory Press on October 26, 2017 -Published by symposium.cshlp.org Downloaded from formation of tumors of up to 20 mm in diameter by 20 weeks (Sotillo et al. 2001b ). Alternative treatments with DMBA plus UVB light also result in the development of similar tumors, albeit with reduced efficiency. No melanocytic tumors are observed after single treatments with either DMBA or UVB light alone.
Histological examination of these lesions confirmed the presence of melanomas in 70% of carcinogen-treated Cdk4 R24C/R24C mice (Sotillo et al. 2001b) . Unlike other models of melanoma, these tumors are highly melanotic, a property that makes them more reminiscent of those observed in humans. Moreover, as observed in human melanomas, the percentage of melanotic cells decreases in advanced malignancies, since active proliferation and melanocyte dedifferentiation often result in decreased production of melanin. In the more advanced melanomas, Cdk4 R24C/R24C tumors are highly cellular, mainly composed of proliferating atypical melanocytes, frequently spindle-shaped with low or no load of melanin. Mitotic figures and areas of necrosis can be easily found. In these cases, melanocyte proliferation is usually invasive to neighbor tissues with infiltrating margins. The neuroectodermal origin of the melanomas is confirmed by positive immunological staining for the S100 antigen. Molecular analysis of Cdk4 R24C/R24C melanomas did not reveal either deletion, rearrangement or promoter methylation in p16 INK4a , p15 INK4b , or p19 ARF loci (Sotillo et al. 2001b ). Although these results are expected for those genes encoding upstream INK4 regulators, the absence of p19 ARF inactivation suggests that alterations in the p53 pathway are not needed for induction and/or progression of these melanomas.
GENETIC ANALYSIS OF THE ROLE OF Cdks IN VIVO
Targeting the cell cycle is an attractive strategy to block neoplastic growth, since most human tumors carry molecular alterations in genes that regulate cell cycle commitment. Unfortunately, most cell cycle regulators altered in human cancer, such as loss of p27 Kip1 , p16 Ink4a , or pRb expression, overexpression of cyclin D and cyclin E, etc., are not amenable to classic pharmacological approaches. On the other hand, the Cdks, regardless of whether they are mutated or not, are suitable targets for therapeutic intervention. Indeed, kinase inhibition has already been successfully used for therapeutic purposes in many diseases, including cancer (e.g., Gleevec). Yet, our current knowledge of the cell cycle is not sufficient to ensure the development of optimal strategies. For instance, we do not know which Cdk inhibitors will provide the best therapeutic benefit or whether it would be more efficacious to block two or several Cdks at the same time.
To gain further knowledge about the role of individual Cdks in the proliferation of normal and tumor cells, we have embarked on the systematic analysis of each of the four cell cycle Cdks: Cdk1, Cdk2, Cdk4, and Cdk6, at the genetic level using gene-targeted strategies in embryonic stem cells. A fifth Cdk also implicated in the cell cycle
WIDESPREAD TUMOR INDUCTION IN MICE EXPRESSING A MISREGULATED Cdk4 KINASE
Most human tumors have genetic and/or epigenetic alterations in the cyclin D-INK4-Cdk4/6-pRb pathway. As indicated above, a miscoding mutation (replacement of Arg-24 by Cys) that renders Cdk4 resistant to INK4 inhibitors is associated with the development of human melanoma. To study the effects of such mutation in the regulation of the cell cycle in particular and in tumorigenesis in general, we have engineered knockin mice that carried this mutation within the endogenous mouse Cdk4 locus (Rane et al. 1999) . Cdk4 R24C/R24C mice are born at the expected Mendelian ratio, are fertile, and develop normally. However, these mice developed detectable tumors after 8 months and most of them died by 16 months of age (Sotillo et al. 2001a ). Necropsy of more than 100 Cdk4 R24C/R24C mice showed a wide spectrum of tumors, including malignancies of mesenchymatous origin (67% incidence); epithelial endocrine (55%); epithelial non-endocrine (24%), and, to a lesser extent, hematopoietic malignancies (3%). Many mice exhibit multiple tumors of independent origin, with an average of almost two tumors per animal. A cohort of 50 mice sacrificed at 14-16 months of age without external signs of disease revealed a similar tumor distribution pattern, except for reduced incidence of sarcomas and pituitary tumors, suggesting that these malignancies are a major cause of death in Cdk4 R24C/R24C mice. Cdk4 +/R24C mice also succumbed to the same types of malignancies, although with increased latency (Sotillo et al. 2001a) .
Cdk4 misregulation synergizes with mutations in other cancer genes such as p53. Double mutant Cdk4
R24C/R24C
;p53 -/-mice die before reaching 4 months of age, significantly earlier than their Cdk4
-/-littermates (Sotillo et al. 2001a) . These mice display an increased number of sarcomas, mainly hemangiosarcomas and leiomyosarcomas. Moreover, a significant fraction of these double mutant mice (10%) develop immature teratomas, a tumor not found in any of their single mutant siblings, although a low incidence of teratomas (<2%) has been described previously in p53 -/-mice. These results suggest that these key regulators exert growth control at different threshold levels in different cell types.
A MUTANT Cdk4R24C KINASE INDUCES INVASIVE MELANOMAS IN MICE
Interestingly, Cdk4 R24C/R24C mice do not develop melanomas, the type of tumor induced by this very same mutation in humans. To determine whether these observations were a consequence of intrinsic mechanistic differences between human and rodents or of phenotypic differences, we submitted the skin of these mutant mice to carcinogenic insults. Specifically, Cdk4 R24C/R24C mice were treated with 7,12-dimethylbenz[a]anthracene (DMBA) followed by repeated exposure to 12-O-tetradecanoylphorbol-13-acetate (TPA), a treatment known to induce the rapid development of skin papillomas. Unlike wild-type mice, Cdk4 R24C/R24C animals develop a high number of nevi that rapidly grow in size, leading to the (Ren and Rollins 2004) , Cdk3, is mutated in most strains of laboratory mice (Ye et al. 2001 ) and will no longer be considered here. Below is a summary of the main results derived from characterizing strains of mice lacking Cdk4, Cdk6, or Cdk2, as well as of double mutant strains lacking Cdk4 and Cdk6 (Cdk4 -/-;Cdk6 -/-), Cdk2 and Cdk6 Cdk2 -/-;Cdk6 -/-), and Cdk2 and its inhibitors p27
Kip1
(Cdk2 -/-;p27 Kip1-/-) and p21 Cip1 (Cdk2 -/-;p21 Cip1-/-).
Cdk4 null MICE
Ablation of Cdk4 does not have significant consequences for cell proliferation, at least in mouse embryonic fibroblasts (MEFs). Quiescent Cdk4 null (Cdk4 n/n ) MEFs enter S phase with slightly delayed kinetics but proliferate normally (Rane et al. 1999; Tsutsui et al. 1999) . In vivo, Cdk4 n/n mice are viable, indicating that Cdk4 is not essential for proliferation of most cell types (Rane et al. 1999; Tsutsui et al. 1999 ). Yet, these mice have limited populations of certain endocrine cell types. For instance, adult Cdk4 n/n mice become diabetic due to reduced numbers of insulin-producing pancreatic β-cells (Rane et al. 1999; Tsutsui et al. 1999) . Subsequent studies have indicated that Cdk4 is essential for postnatal proliferation of pancreatic β-cells but not for their neogenesis from ductal epithelial cells . Interestingly, Cdk6 expression is basically undetectable in postnatal pancreatic β-cells, thus providing a possible explanation for their strict dependence on Cdk4 expression.
Cdk4 null mice also have decreased male fertility due to defective spermatogenesis and reduced numbers of Leydig cells (Rane et al. 1999; Tsutsui et al. 1999) . Female Cdk4 n/n mice are completely sterile due to limited prolactin production, a consequence of their reduced numbers of pituitary lactotrophs (Moons et al. 2002; Jirawatnotai et al. 2004) . As in the case of pancreatic β-cells, Cdk4 is essential for postnatal proliferation of the anterior pituitary, but it is not required for embryonal development of the pituitary gland (Moons et al. 2002) . Interestingly, siRNA-mediated knockdown of Cdk4, but not of Cdk6, inhibits GHRH-induced proliferation of GH3 somato/lactotroph cells with restored expression of GHRH receptors, thus suggesting distinct functional roles for these highly related kinases within the same cellular context (Jirawatnotai et al. 2004) .
Finally, Cdk4 n/n mice are considerably smaller than their wild-type littermates (Rane et al. 1999; Tsutsui et al. 1999 ). This phenotype is not a consequence of the hormonal defects of Cdk4 null animals. Cdk4 n/n ;Rip-Cre mice, in which an active Cdk4 kinase is re-expressed in pancreatic β-cells and in pituitary lactotrophs, are normoglycemic and fully fertile, yet they retain their small-size phenotype . Since the size of Cdk4 null cells appears to be similar to that of wild-type cells, it is possible that Cdk4 plays a role in controlling homeotic cell numbers, at least in mice.
Cdk6 null MICE
Mice lacking Cdk6 develop normally and are viable, although hematopoiesis is slightly impaired (Malumbres et al. 2004 ). This is a somewhat expected result, since Cdk6 is most abundantly expressed in lymphoid organs. In Cdk6-deficient mice, the thymus is reduced in size due to lower cellularity, and its cortical area is atrophic in about one-third of the mutant animals. Their spleens are also reduced in size due to decreased cell density in the red pulp. Whereas in wild-type mice, 70-75% of all spleen cells belong to the erythroid lineage, these figures decrease to 35-40% in Cdk6 -/-littermates. Similarly, the number of megakaryocytes is severely reduced to less than one-third of those present in wild-type spleens (Malumbres et al. 2004) . Cdk6 null mice also exhibit lower numbers of red cells (about 15%) in peripheral blood. Interestingly, Cdk6 -/-mice do not display obvious deficiencies in the bone marrow. In vitro, Cdk6 null lymphocytes, but not Cdk6 -/-MEFs, show delayed entry in the cell cycle upon mitogenic stimulation (Malumbres et al. 2004 ).
LATE EMBRYONIC LETHALITY OF Cdk4;Cdk6

DOUBLE MUTANT MICE
Mice lacking both cyclin D-dependent kinases, Cdk4 and Cdk6, are not viable. Yet, Cdk4 n/n ;Cdk6 -/-double mutant embryos develop to midgestation with the expected Mendelian frequency, suggesting that they do not have intrinsic cell cycle defects (Malumbres et al. 2004 ). The percentage of dead embryos increases during late embryonic development. Although some Cdk4 n/n ;Cdk6 -/-pups can make it to term, all of them have been found to be dead at birth. These double null embryos/pups and their corresponding placentas are well formed and do not present significant abnormalities. Moreover, all tissues, except for those of hematopoietic origin, display normal levels of proliferating and apoptotic cells. E14.5 to E18.5 Cdk4 n/n ;Cdk6 -/-embryos have structurally aberrant livers with decreased levels of erythroid precursors. Peripheral blood also reveals a dramatic decrease in the number of red blood cells that display a megaloblastic feature typical of anemia. These findings suggest that Cdk4 n/n ;Cdk6 -/-embryos die during the late stages of embryonic development due to limited proliferation of erythroid progenitors.
The relative numbers of Cdk4 n/n ;Cdk6 -/-hematopoietic stem cells (HSCs) appear to be normal, although their absolute numbers are decreased due to the lower cellularity of the mutant livers (around 15%). However, the levels of other Cdk4/Cdk6 null lineage-committed progenitors are reduced beyond those levels expected from the decreased cellularity (Malumbres et al. 2004) . Accordingly, the numbers of more mature hematopoietic cells, such as monocytes, macrophages, or lymphocytes, are also reduced. Interestingly, the phenotype of Cdk4 n/n ;Cdk6 -/-double knockout mice is very similar to that observed in mice lacking the three D-type cyclins (Kozar et al. 2004 ). Yet, D-type cyclin-depleted embryos exhibit a more dramatic reduction of hematopoietic cells. Whether the formation of Cdk2/cyclin D complexes (see below) contributes to alleviate the requirement for Cdk4 and Cdk6 in hematopoietic cells remains to be determined.
Cdk4 AND Cdk6 DEFECTIVE MEFs
Early passage Cdk4 n/n ;Cdk6 -/-MEFs proliferate well, albeit at a slower rate than control cells (Malumbres et al. 2004) . Moreover, all Cdk4 n/n ;Cdk6 -/-double mutant MEFs can immortalize upon continuous passage in culture. These MEFs also proliferate in low serum conditions and respond to mitogenic stimuli induced by addition of EGF and IGF-1. Moreover, they enter S phase upon mitogenic stimulation with normal kinetics, albeit less efficiently than wild-type cells. These observations, taken together, indicate that the D-type cyclin-dependent kinases are not essential either for cell proliferation or for re-entry in the cell cycle, at least in MEFs.
Ablation of Cdk4 and Cdk6 does not affect expression of D-type cyclins. These cyclins, in the absence of their cognate partners, form functional complexes with Cdk2 (Malumbres et al. 2004) . Indeed, these Cdk2/cyclin D kinases phosphorylate pRb, at least in vitro. Moreover, Cdk2 shRNA significantly decreases the rate of BrdU incorporation in Cdk4 n/n ;Cdk6 -/-MEFs. These observations suggest that in the absence of Cdk4 and Cdk6, Cdk2, in association with D-type cyclins, may help to drive cells through the early phases of the cell cycle. Yet, confirmation of this hypothesis must await genetic scrutiny; for instance, by generating Cdk4/Cdk6/Cdk2 triple mutant mice.
ABLATION OF THE Cdk2 LOCUS REVEALS Cdk2 AS AN ESSENTIAL MEIOTIC KINASE
Cdk2
-/-mice are born at the expected Mendelian ratio, indicating that Cdk2 is not essential for cell proliferation in most, if not all, tissues (Berthet et al. 2003; . Moreover, these mutant mice do not display gross anatomical or behavioral abnormalities for up to 2 years of life except for severe atrophy in their gonads that results in complete sterility. Spermatogenesis defects in Cdk2 -/-male mice become visible at P20, a time when germ cells have completed meiosis I. P20 Cdk2 -/-animals do not have round spermatids in the seminiferous tubules, and there is massive apoptosis of spermatocytes . Analysis of spermatocytes from adult mice by immunoconfocal microscopy shows leptotene, zygotene, and pachytene stages, but no diplotene or later meiotic stages. Studies using immunohistochemical markers firmly established that the absence of Cdk2 triggers the pachytene checkpoint responsible for the massive apoptosis observed in Cdk2 -/-spermatocytes .
Cdk2 -/-oocytes develop normally through the leptotene, zygotene, and pachytene stages (E14.5-E18.5). However, when oocytes reach the dictyate stage (P1-P2), Cdk2 mutant oocytes display multiple defects (desynapsed fibers, randomly distributed centromeres, etc.) which indicate that Cdk2 -/-oocytes also have a defect in prophase I, albeit at a later developmental stage . These observations establish that Cdk2 is essential for completion of the first meiotic division in both male and female germ cells.
Interestingly, mice deficient for both E-type cyclins are not viable, most likely due to a defect in the endoreplication of placental trophoblast giant cells (Geng et al. 2003; Parisi et al. 2003) . These observations provide genetic evidence for a differential role of Cdk2 and E-type cyclins, at least during endoreplication. This suggests that E-type cyclins must have a partner(s) other than Cdk2. Whether such partners are Cdks, and whether they are functional in cells other than trophoblasts, remain to be determined.
Cdk2 IS DISPENSABLE FOR THE MITOTIC CELL CYCLE
Primary Cdk2 -/-MEFs grow well in culture and proliferate with kinetics similar to those of wild-type cells (Berthet et al. 2003; Ortega et al. 2003) . Serum-starved Cdk2 -/-MEFs enter S phase with the same kinetics as their wild-type counterparts upon serum stimulation.
Cdk2
-/-MEFs also become immortalized upon continuous passage in culture. Indeed, we have only observed subtle differences in the timing at which these cells enter culture crisis. Moreover, removal of Cdk2 from Cdk2 lox/-MEFs does not have significant consequences in their proliferative properties, indicating that Cdk2 is dispensable for cell proliferation in conditions in which plasticity is unlikely to play a role ). E-type cyclin-deficient MEFs also proliferate well in culture. However, these cells have a defect in cell cycle re-entry, presumably due to a failure in loading MCM proteins onto DNA replication origins (Geng et al. 2003 ). These observations provide additional genetic evidence for the existence of E-type cyclin partners other than Cdk2. Whether the putative cyclin E partners responsible for this cell cycle defect are the same as those required for endoreplication remains to be determined.
ABSENCE OF SYNERGISM BETWEEN Cdk6 AND Cdk2 DEFICIENCIES
Crosses between Cdk6 +/-;Cdk2 +/-heterozygous mice yield Cdk6 -/-;Cdk2 -/-double null animals with expected Mendelian ratios. Mice defective for Cdk6 and Cdk2 display those phenotypical abnormalities previously observed in Cdk6 and Cdk2 single mutant strains Malumbres et al. 2004) . Briefly,
Cdk6
-/-;Cdk2 -/-animals are sterile and show marked defects in spermatogenesis and oogenesis, basically indistinguishable from those reported for Cdk2-deficient mice . They also have limited defects in hematopoietic cells similar to those described above for Cdk6 null mice. Finally, Cdk6
-/-;Cdk2 -/-animals survive for up to 1.5 years without developing obvious additional abnormalities (Malumbres et al. 2004 ).
Cdk2 IS ALSO DISPENSABLE FOR CELL CYCLE REGULATION MEDIATED BY Cip/Kip INHIBITORS
The above results challenge the central roles attributed to Cdk2 in cell cycle progression. One such role involves mediating the inhibitory properties and tumor-suppress-ing activities of p21
Cip1 and p27 Kip1 , the best characterized members of the Cip/Kip family of cell cycle inhibitors (Sherr and Roberts 1999) . Infection of primary MEFs with retroviruses expressing p21
Cip1 or p27
Kip1 proteins halts their proliferation regardless of the presence or absence of Cdk2 (Martín et al. 2005) . About half of the Cdk2 -/-MEFs are halted in G 2 /M, a result likely due to inhibition of Cdk1. However, most Cdk2 -/-cells (60%) are arrested in G 1 . Genetic evidence argues against a compensatory role of Cdk4 and Cdk6, since p27
Kip1 and p21
Cip1 effectively block cell proliferation in MEFs lacking either Cdk4 and Cdk6, or the three D-type cyclins (Kozar et al. 2004; Malumbres et al. 2004 MEFs enter S phase 4-6 hours earlier than wild-type cells upon serum stimulation (Martín et al. 2005) , indicating that the shortening in S phase entry cannot be mediated by constitutive activation of Cdk2.
Cdk2 IS NOT ESSENTIAL FOR p21
Cip1 -MEDIATED CELL CYCLE ARREST AFTER DNA DAMAGE p21 Cip1 is one of the major effectors of cell cycle arrest induced following DNA damage. Double mutant p21
Cip1-/-;Cdk2 -/-cells display the same levels of BrdU incorporation as p21
Cip1-/-MEFs upon exposure to gamma radiation or to etoposide treatment. Moreover, these double mutant cells also fail to arrest in G 1 after these treatments (Martín et al. 2005 ). These observations provide genetic evidence against the concept that p21 Cip1 mediates cell cycle arrest at the DNA damage checkpoint by blocking Cdk2 activity.
THE TUMOR SUPPRESSOR ACTIVITY OF p27 Kip1 DOES NOT REQUIRE Cdk2
Mice defective for p27 Kip1 are bigger in size, display organomegaly and retinal defects, and develop frequent pituitary tumors (Fero et al. 1996; Kiyokawa et al. 1996; Nakayama et al. 1996) . p27
Kip1-/-;Cdk2 -/-double mutant mice weigh, on average, 50-60% more than wild type and display widespread organomegaly similar to p27
Kip1-/-null animals, except in testis and ovaries which were as hypotrophic as in Cdk2 -/-mice (Martín et al. 2005) . p27
Kip1-/-;Cdk2 -/-mutant animals display the same retinal defects observed in p27
Kip1 null mice and with similar penetrance (about 10%) (Kiyokawa et al. 1996; Nakayama et al. 1996) . More importantly, these double mutant mice develop pituitary tumors with the same high penetrance and latency as p27
Kip1 single mutant animals (Martín et al. 2005 
CONCLUSIONS Cell Cycle Mutations and Cancer
Cancer is frequently considered as a cell cycle disease. Although many cell cycle regulatory mechanisms have been studied at length in vitro, it is still unclear how they are coordinately regulated in vivo and how their misregulation leads to human cancer. Evidence accumulated over the last decade has clearly illustrated that mutation of the same cell cycle regulators known to be mutated or epigenetically altered in human cancer also leads to tumor development in mice (Ortega et al. 2002) . For instance, pRb +/- (Jacks et al. 1992; Lee et al. 1992 ), Cdk4 R24C/R24C (Rane et al. 1999; Sotillo et al. 2001a) , and Ink4a/Arf -/- (Serrano et al. 1996) mice develop tumors with complete penetrance. Other mutations, such as those ablating the INK4 inhibitors p16
Ink4a and p15 Ink4b , have not led to overt tumor development (Latres et al. 2000; Krimpenfort et al. 2001; Sharpless et al. 2001 ) but seem to predispose to cancer. Whether these mutations in humans only contribute to carcinogenesis in the presence of other mutations remains to be determined. Finally, amplification of cyclin D1 or cyclin E in mice also leads to abnormal growth, albeit not to overt tumor growth, suggesting that they are contributors, but not "primary drivers" of carcinogenesis.
Cdks and the Regulation of the Cell Cycle
Genetic analysis of the role of Cdks has provided a series of observations that are not compatible with widely accepted models for the mammalian cell cycle. Mainly, neither the D-type cyclins nor their cognate cyclin D-dependent kinases, Cdk4 and Cdk6, are essential for cell proliferation or exit from quiescence in most cell types. Only cells of hematopoietic origin appear to require at least one of these D-type cyclins or their kinase partners for proper proliferation. Several issues need to be addressed before we can fully evaluate the requirements for the D-type cyclin-dependent kinases in mammalian cells. For instance, we need to determine whether they are required in adult tissues, since it could be argued that during embryonic development most cells do not exit the cycle. Alternatively, it is possible that exit from quiescence during embryogenesis might be regulated by mechanisms distinct from those that regulate cell cycle re-entry in adult cells.
It is also possible that in the absence of Cdk4 and Cdk6, cellular plasticity allows Cdk2 to interact with the D-type cyclins and to compensate for their absence. Likewise, it could be argued that the Cdk2/cyclin E kinases may functionally compensate for the lack of D-cyclin-dependent kinase activity (Geng et al. 1999) . Generation of triple Cdk4/Cdk6/Cdk2 null mice should help to resolve some of these issues.
Regardless of potential compensatory effects by other Cdks, or even by other less related kinases, the absolute dispensability of Cdk2 in mitotic cells in vivo is an unexpected finding. Despite extensive bibliography linking Cdk2 to many critical cellular processes such as DNA replication and centrosome duplication (Sherr and Roberts 1999) , available genetic evidence to date has failed to demonstrate a role for Cdk2 in these processes. Equally surprising have been recent genetic observations indicating that Cdk2 is not essential for mediating the cell cycle inhibitory properties of the Cip/Kip inhibitors p21
Cip1 and p27
Kip1 (Aleem et al. 2005; Martín et al. 2005) . Likewise, the presence or absence of Cdk2 has no effect on the incidence or latency of pituitary tumors caused by loss of p27 Kip1 . These observations have direct implications in the design of therapeutic strategies to fight tumors in which there is loss of p27
Kip1 expression, or even loss of P53, since this tumor suppressor controls the synthesis of p21
Cip1 . Although the essential targets for p21 Cip1 and p27
Kip1 tumor suppressors remain to be identified, it is likely that they block cell cycle progression, at least partially, by inhibiting Cdk1. Whether inhibition of Cdk1 will have a selective effect on tumor cells is a key issue that should be addressed by genetic means before selective inhibitors are developed.
In summary, our results illustrate the need to continue interrogating the cell cycle by genetic means. An integrated view from biochemical studies, experimental animal models, and the analysis of cancer mutations will undoubtedly help to exploit this knowledge to develop rational therapeutic approaches with which to target those tumors exhibiting a deregulated cell cycle.
